Late Menopause Linked to 48% Higher Risk of Metabolic Multimorbidity in Chinese Women

For decades, women who reached menopause later in life were often told the news was largely good: a longer exposure to estrogen has been associated with stronger bones, healthier blood vessels, and slower skin aging. But a large new study from China adds a striking caveat to that conventional wisdom. Researchers analyzing data from thousands of postmenopausal women found that those whose periods stopped after age 55 faced a substantially elevated risk of developing multiple metabolic disorders at once, a condition known as metabolic multimorbidity. The findings, published in BMC Medicine, suggest that the timing of the menopausal transition may shape metabolic health in ways that are more complicated, and potentially more consequential, than previously appreciated.

The study, led by Cesar Camilo Calderon Torres and Yang Guo of Hebei Medical University together with Jiashuo Huang and Jie Chang of Capital Medical University, drew on the China Health and Retirement Longitudinal Study, one of the country’s most important population health surveys. The team followed 6,298 postmenopausal women across survey waves from 2011 to 2018, tracking whether and when they developed combinations of hypertension, diabetes, and dyslipidemia, the three metabolic conditions that together drive much of the global burden of cardiovascular disease. Metabolic multimorbidity was defined as the co-occurrence of two or more of these disorders, a state that is far more dangerous than any single condition alone because the diseases amplify one another’s effects on the heart, kidneys, and brain.

To measure the relationship between menopause timing and disease risk, the researchers categorized self-reported age at menopause into three groups: early menopause before age 45, normal menopause between 45 and 55, and late menopause after 55. They then applied Cox proportional hazards models, a statistical technique that estimates how a given exposure changes the rate at which an event occurs over time, adjusting for a battery of sociodemographic and lifestyle factors including education, residence, body mass index, and health behaviors. This adjustment is critical in observational research, because women with different menopause timing may also differ in weight, smoking habits, socioeconomic status, and access to healthcare, any of which could confound the apparent relationship.

The results were unambiguous for late menopause. Over 12,632 person-years of follow-up, 583 women developed metabolic multimorbidity, and those who experienced menopause after age 55 had a 48 percent higher risk of doing so compared with women whose menopause fell in the normal window. The adjusted hazard ratio of 1.48, with a 95 percent confidence interval of 1.08 to 2.02, indicates a statistically robust association. Perhaps even more telling was the dose-response analysis: each additional year of age at menopause was associated with a 2 percent increase in multimorbidity risk. Restricted cubic spline analyses, which model the shape of the relationship between exposure and outcome without forcing it into a straight line, supported a pattern in which risk climbs steadily with later menopause timing.

When the researchers broke the outcome down into its individual components, the picture became more nuanced. Late menopause was most strongly linked to diabetes, with a hazard ratio of 1.49, meaning women with late menopause had roughly a 49 percent higher risk of developing the disease. Hypertension showed a more modest but still detectable linear increase, with each additional year of menopause age raising risk by about 1 percent. Dyslipidemia, by contrast, showed no significant association with menopause timing. This pattern is biologically plausible: prolonged ovarian estrogen production influences fat distribution, insulin sensitivity, and glucose metabolism, and extended exposure may promote the gradual accumulation of visceral adiposity and insulin resistance that culminates in type 2 diabetes.

What makes the finding counterintuitive is the long-standing assumption that later menopause is cardioprotective. Estrogen is known to exert favorable effects on lipid profiles and vascular function during reproductive years, and early surgical or natural menopause has repeatedly been tied to elevated cardiovascular risk. The new study did not contradict that literature entirely, because early menopause showed no significant association with metabolic multimorbidity in this cohort, with a hazard ratio of 0.93 that crossed the line of statistical significance. Instead, the data suggest a more complex curve in which both ends of the menopause timing spectrum may carry different types of risk, with late menopause favoring metabolic disease and early menopause potentially favoring other cardiovascular outcomes that this study did not measure.

The authors also examined whether the association varied across subgroups defined by educational level or urban versus rural residence, and found no significant interactions. That consistency matters for public health planning in China, where the population is aging rapidly and metabolic diseases are rising in both cities and the countryside. If the relationship between late menopause and metabolic multimorbidity holds across social strata, then menopause timing could serve as a simple, zero-cost marker that clinicians can record during routine history-taking to identify women who warrant closer metabolic surveillance in later life.

Several caveats deserve attention. Age at menopause was self-reported, and recall error is a known limitation in retrospective studies of reproductive history, particularly among older women surveyed years after the event. The CHARLS cohort is community-dwelling and middle-aged to older, so the findings may not generalize to women who died before recruitment or who experienced very early surgical menopause. Observational designs also cannot rule out residual confounding by factors such as parity, breastfeeding history, oral contraceptive use, or hormone therapy, none of which can be fully captured in a general aging survey. And because the outcome was incident multimorbidity during a relatively short follow-up window, longer studies will be needed to confirm whether the association persists and strengthens with age.

Even with those limitations, the study offers a valuable reframing of menopause as a metabolic event, not merely a reproductive one. The menopausal transition is increasingly recognized as a window of heightened vulnerability, when shifts in estrogen, body composition, and sleep converge to accelerate cardiometabolic risk. By showing that the timing of that transition predicts the likelihood of accumulating multiple metabolic diseases simultaneously, the researchers provide a concrete signal that preventive strategies, including glucose screening, blood pressure monitoring, and lifestyle counseling, could be tailored to menopause history. For the millions of women worldwide who experience late natural menopause, the message is not alarm but awareness: a longer reproductive lifespan may carry a metabolic bill that arrives later in life, and knowing that in advance is the first step toward paying it down early.

Subject of Research: The association between age at menopause and metabolic multimorbidity risk in Chinese postmenopausal women

Article Title: Age at menopause and major metabolic disorders among Chinese middle-aged and older women

Article References: Torres, C. C. C., Huang, J., Chang, J., & Guo, Y. (2026). Age at menopause and major metabolic disorders among Chinese middle-aged and older women. BMC Medicine. https://doi.org/10.1186/s12916-026-05225-9

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05225-9

Keywords: menopause, metabolic multimorbidity, diabetes, hypertension, dyslipidemia, women's health, China, CHARLS, estrogen exposure, aging, epidemiology, Cox proportional hazards